Blue Owl Capital Holdings LP Sells 35,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Blue Owl Capital Holdings LP trimmed its position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) by 13.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 220,000 shares of the company's stock after selling 35,000 shares during the period. Centessa Pharmaceuticals accounts for approximately 0.9% of Blue Owl Capital Holdings LP's holdings, making the stock its 25th biggest position. Blue Owl Capital Holdings LP owned approximately 0.17% of Centessa Pharmaceuticals worth $3,685,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Adage Capital Partners GP L.L.C. lifted its stake in shares of Centessa Pharmaceuticals by 22.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company's stock worth $85,744,000 after acquiring an additional 924,027 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Centessa Pharmaceuticals by 14.6% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company's stock worth $89,854,000 after acquiring an additional 685,371 shares during the period. Diadema Partners LP acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter worth approximately $2,209,000. Affinity Asset Advisors LLC lifted its stake in shares of Centessa Pharmaceuticals by 13.5% in the 4th quarter. Affinity Asset Advisors LLC now owns 1,095,924 shares of the company's stock worth $18,357,000 after acquiring an additional 130,312 shares during the period. Finally, XTX Topco Ltd lifted its stake in shares of Centessa Pharmaceuticals by 122.9% in the 4th quarter. XTX Topco Ltd now owns 22,680 shares of the company's stock worth $380,000 after acquiring an additional 12,506 shares during the period. 82.01% of the stock is owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Down 0.1 %

CNTA stock traded down $0.02 during trading hours on Tuesday, hitting $13.74. The company's stock had a trading volume of 231,988 shares, compared to its average volume of 606,483. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The company has a market capitalization of $1.83 billion, a PE ratio of -8.98 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12 month low of $7.75 and a 12 month high of $19.09. The stock has a 50 day moving average price of $14.38 and a two-hundred day moving average price of $15.86.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its earnings results on Monday, March 24th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.04. On average, equities research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Saurabh Saha sold 14,656 shares of the company's stock in a transaction on Monday, April 21st. The shares were sold at an average price of $12.29, for a total transaction of $180,122.24. Following the completion of the sale, the chief executive officer now directly owns 261,361 shares of the company's stock, valued at approximately $3,212,126.69. This represents a 5.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gregory M. Weinhoff sold 11,742 shares of the firm's stock in a transaction on Friday, April 25th. The shares were sold at an average price of $13.61, for a total transaction of $159,808.62. Following the completion of the transaction, the insider now owns 122,279 shares in the company, valued at $1,664,217.19. The trade was a 8.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 213,824 shares of company stock valued at $3,497,018 over the last ninety days. Corporate insiders own 11.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a report on Monday, March 31st. They set an "overweight" rating and a $38.00 price target on the stock. Guggenheim reiterated a "buy" rating and issued a $28.00 price objective on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Morgan Stanley reiterated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research note on Friday, March 7th. Finally, TD Cowen initiated coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a "buy" rating on the stock. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $27.71.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.